Effectiveness and Impact of the 4CMenB Vaccine against Group B Meningococcal Disease in Two Italian Regions Using Different Vaccination Schedules: A Five-Year Retrospective Observational Study (2014-2018)

被引：50

作者：

Azzari, Chiara ^{[1
,2
]}

Moriondo, Maria ^{[1
]}

Nieddu, Francesco ^{[1
,2
]}

Guarnieri, Valentina ^{[1
]}

Lodi, Lorenzo ^{[1
]}

Canessa, Clementina ^{[1
,2
]}

Indolfi, Giuseppe ^{[2
,3
]}

Giovannini, Mattia ^{[1
]}

Napoletano, Giuseppina ^{[4
]}

Russo, Francesca ^{[4
]}

Baldovin, Tatjana ^{[5
]}

Cocchio, Silvia ^{[5
]}

Ricci, Silvia ^{[1
,2
]}

Baldo, Vincenzo ^{[5
]}

机构：

[1] Univ Florence, Dept Hlth Sci, Sect Pediat, Viale Pieraccini 24, I-50139 Florence, Italy

[2] Meyer Childrens Hosp, Immunol & Mol Microbiol Unit, Viale Pieraccini 24, I-50139 Florence, Italy

[3] Univ Florence, Dept Neurofarba, Sect Pediat, Viale Pieraccini 24, I-50139 Florence, Italy

[4] Veneto Reg Hlth Author, Prevent Dept, Via Don Tosatto 147, I-30174 Venice Mestre, Italy

[5] Univ Padua, Dept Cardiac Thorac Vasc Sci & Publ Hlth, Publ Hlth Sect, Via Leonardo Loredan 18, I-35131 Padua, Italy

来源：

VACCINES | 2020年 / 8卷 / 03期

关键词：

meningococcus B; vaccination schedule; children; vaccine effectiveness; vaccine impact; ENGLAND;

D O I：

10.3390/vaccines8030469

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background: A few years after the introduction in Italy of a four-component anti-meningococcal B vaccine (4CMenB), we evaluated the effectiveness and impact of vaccination in two regions using different schedules (2, 4, 6, 12 months in Tuscany vs. 7, 9, 15 months in Veneto) through an observational retrospective study. Methods: Vaccination started in 2014 in Tuscany and in 2015 in Veneto; the data collected referred to the period 2006-2018 for Tuscany and 2007-2018 for Veneto. Cases of invasive meningococcal disease due to N. Meningitidis B were identified by culture and/or real-time PCR. Results: In Tuscany, pre-vaccine incidence was 1.96 (95% CL 1.52; 2.40) and dropped to 0.62 (95% CL 0.60; 0.64) in the post-4CMenB era. Evaluating only vaccinated children, post-4CMenB incidence was 0.12 (95% CL 0.08; 0.15). In Veneto pre-vaccine incidence was 1.94 (95% CL 1.92; 1.96) and dropped to 1.34 (95% CL 1.31; 1.38) in the post-4CMenB era. In the vaccinated population, MenB incidence was 0.53 (95% CL 0.50; 0.56). Vaccine effectiveness was 93.6% (95% CL 55.4; 99.1) in Tuscany and 91.0% (95% CL 59.9; 97.9) in Veneto, with mean vaccine coverages of 83.9% and 81.7%, respectively. The overall impact (evaluating both vaccinated and unvaccinated children) was 0.68 (95% CL 0.10; 0.89) in Tuscany and 0.31 (95% CL -0.56; 0.69) in Veneto; the total impact (evaluating only vaccinated children) was 0.94 (95% CL 0.56; 0.99) and 0.90 (95% CL 0.57; 0.97), respectively. The relative case reduction (RCR) was 65% in Tuscany and 31% in Veneto. Considering the vaccinated population, the RCR was equal to 91% and 80%, respectively. Conclusion: In conclusion, 4CMenB appears to have a very high effectiveness in Italy; the impact of vaccination appears greater where the immunization program is started early.

引用

页码：1 / 12

页数：12